TFS
CRSP icon

Thoroughbred Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Thoroughbred Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,065
Closed -$231K – 338
2021
Q3 		$231K Sell
2,065
-196
-9% -$24.6K 0.06% 285
2021
Q2 		$366K Buy
2,261
+75
+3% +$9.12K 0.09% 210
2021
Q1 		$266K Buy
+2,186
New +$330K 0.07% 231

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Thoroughbred Financial Services's CRSP Position: Q4 2021 in Review

Thoroughbred Financial Services sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 2,065 shares — an estimated $231K sold.

Thoroughbred Financial Services first reported a position in CRSP in Q1 2021 and held it in 3 quarters. The position peaked at $366K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Thoroughbred Financial Services reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Thoroughbred Financial Services sold 2,065 CRISPR Therapeutics shares in Q4 2021, an estimated $231K.
  • Thoroughbred Financial Services first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 3 quarters.
  • Thoroughbred Financial Services's CRISPR Therapeutics position peaked at $366K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Thoroughbred Financial Services's 13F filing for Q4 2021, filed 9 Feb 2022.